

Current Report No 16/2022**Obtaining patent protection for an invention from the European Patent Office.**

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wroclaw, Poland, hereby reports that The Company has learned about the validity of a patent for an invention entitled "A method of detecting genetic material in a biological sample and a device for its implementation" in Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Montenegro, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Netherlands, Norway, Portugal, Romania, San Marino, Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom.

The Issuer informed about the positive decision regarding granting of the patent by the European Patent Office in the report 2/2022, however the final stage granting patent protection in a particular country was the validation mentioned above.

The invention covers the key technical solutions related to the proprietary contactless heating and temperature detection system developed for POCT platforms, including Genomtec®ID.

The Issuer's Management Board decided that the receipt of the above validation is confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual and industrial property. Properly secured intellectual and industrial property may constitute the Issuer's competitive advantage - and its safe commercialization is possible provided that full protection is ensured on selected markets.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners in the scope of implementing the commercialization strategy.

Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. POCT diagnostics using the Genomtec®ID platform is the key area of the Issuer's operations. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.